Cargando…
Direct acting anti-hepatitis C combinations as potential COVID-19 protease inhibitors
The coronavirus pandemic could be the most threatening outbreak in the twenty-first century. According to the latest records of world health organization, more than 130 millions have been infected by COVID-19, with more than 2.9 million reported deaths. Yet, there is no magic cure for treatment of C...
Autores principales: | Hamed, Mahmoud, El-Hasab, Mahmoud, Mansour, Fotouh R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer India
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8083918/ https://www.ncbi.nlm.nih.gov/pubmed/33948452 http://dx.doi.org/10.1007/s13337-021-00691-6 |
Ejemplares similares
-
Re-purposing of hepatitis C virus FDA approved direct acting antivirals as potential SARS-CoV-2 protease inhibitors
por: Uddin, Reaz, et al.
Publicado: (2022) -
Efficacy and safety of hepatitis C direct-acting protease inhibitors (DAA-PI ) in real life in HIV-HCV coinfected patients
por: Ménard, A, et al.
Publicado: (2014) -
The Impact of Direct-Acting Antiviral Agents on Cytomegalovirus Reactivation in Chronic Hepatitis C Infection
por: Dawood, Reham M, et al.
Publicado: (2022) -
Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C
por: Xiao, Fei, et al.
Publicado: (2015) -
Evaluation of Potential Anti-Hepatitis A Virus 3C Protease Inhibitors Using Molecular Docking
por: Sasaki-Tanaka, Reina, et al.
Publicado: (2022)